Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Section 6 of 6

References

261 sources

  1. Aaronson et al. (2017) (opens in a new tab)
  2. Aaronson et al. (2025) (opens in a new tab)
  3. Abilify prescribing information (2025) (opens in a new tab)
  4. Akil et al. (2018) (opens in a new tab)
  5. American Psychiatric Association (2010) (opens in a new tab)
  6. Amos et al. (2018) (opens in a new tab)
  7. Anand et al. (2023) (opens in a new tab)
  8. Avanceña et al. (2025) (opens in a new tab)
  9. Becker et al. (2022) (opens in a new tab)
  10. Benson et al. (2020) (opens in a new tab)
  11. Bergfeld et al. (2016) (opens in a new tab)
  12. Bergfeld et al. (2018) (opens in a new tab)
  13. Blumberger et al. (2018) (opens in a new tab)
  14. Borgogna et al. (2025) (opens in a new tab)
  15. Bosco-Lévy et al. (2021) (opens in a new tab)
  16. Brenner et al. (2021) (opens in a new tab)
  17. Brenner et al. (2026) (opens in a new tab)
  18. Brown et al. (2017) (opens in a new tab)
  19. Brown et al. (2019) (opens in a new tab)
  20. Butler et al. (2022) (opens in a new tab)
  21. Cai et al. (2020) (opens in a new tab)
  22. Cepeda et al. (2018a) (opens in a new tab)
  23. Cepeda et al. (2018b) (opens in a new tab)
  24. Chaikali et al. (2026) (opens in a new tab)
  25. Chamberlain et al. (2019) (opens in a new tab)
  26. Cheng et al. (2024) (opens in a new tab)
  27. Chisamore et al. (2025) (opens in a new tab)
  28. Cleare et al. (2025) (opens in a new tab)
  29. Clemens et al. (2024) (opens in a new tab)
  30. ClinicalTrials.gov NCT03775200 (opens in a new tab)
  31. ClinicalTrials.gov NCT03775200 results (opens in a new tab)
  32. ClinicalTrials.gov NCT04519957 (opens in a new tab)
  33. ClinicalTrials.gov NCT04739865 (opens in a new tab)
  34. ClinicalTrials.gov NCT04959253 (opens in a new tab)
  35. ClinicalTrials.gov NCT05624268 (opens in a new tab)
  36. ClinicalTrials.gov NCT05711940 (opens in a new tab)
  37. ClinicalTrials.gov NCT05733546 (opens in a new tab)
  38. ClinicalTrials.gov NCT07226232 (opens in a new tab)
  39. ClinicalTrials.gov NCT07570654 (opens in a new tab)
  40. CMS 2027 Adult Core Set (opens in a new tab)
  41. CMS vagus nerve stimulation national coverage determination (2019) (opens in a new tab)
  42. Cole et al. (2022) (opens in a new tab)
  43. COMPASS Pathways (2018) (opens in a new tab)
  44. COMPASS Pathways COMP001 protocol (2019) (opens in a new tab)
  45. COMPASS Pathways COMP001 statistical analysis plan (2021) (opens in a new tab)
  46. COMPASS Pathways COMP005 52-week release (2026) (opens in a new tab)
  47. COMPASS Pathways COMP006 26-week presentation (2026) (opens in a new tab)
  48. COMPASS Pathways COMP006 topline presentation (2026) (opens in a new tab)
  49. COMPASS Pathways executive order release (2026) (opens in a new tab)
  50. COMPASS Pathways first quarter 2025 results (2025) (opens in a new tab)
  51. COMPASS Pathways first quarter 2026 results (2026) (opens in a new tab)
  52. COMPASS Pathways Form 10-K (2026) (opens in a new tab)
  53. COMPASS Pathways Form 10-Q (2026) (opens in a new tab)
  54. COMPASS Pathways Form 8-K COMP005 topline (2025) (opens in a new tab)
  55. COMPASS Pathways Form 8-K COMP006 26-week results (2026) (opens in a new tab)
  56. COMPASS Pathways Form 8-K COMP006 topline (2026) (opens in a new tab)
  57. COMPASS Pathways fourth quarter 2025 results (2026) (opens in a new tab)
  58. COMPASS Pathways NDA submission release (2026) (opens in a new tab)
  59. COMPASS Pathways NEJM publication release (2022) (opens in a new tab)
  60. COMPASS Pathways November investor presentation (2026) (opens in a new tab)
  61. COMPASS Pathways phase 3 design release (2022) (opens in a new tab)
  62. COMPASS Pathways PIVOT release (2026) (opens in a new tab)
  63. COMPASS Pathways provider training grant release (2026) (opens in a new tab)
  64. COMPASS Pathways Psych Congress release (2026) (opens in a new tab)
  65. COMPASS Pathways rolling review and voucher release (2026) (opens in a new tab)
  66. COMPASS Pathways second quarter 2024 results (2024) (opens in a new tab)
  67. COMPASS Pathways second quarter 2026 results (2026) (opens in a new tab)
  68. COMPASS Pathways support model publication release (2026) (opens in a new tab)
  69. COMPASS Pathways third quarter 2024 results (2024) (opens in a new tab)
  70. COMPASS Pathways third quarter 2025 results (2025) (opens in a new tab)
  71. COMPASS Pathways third quarter 2026 results (2026) (opens in a new tab)
  72. COMPASS Pathways third quarter earnings call transcript (2026) (opens in a new tab)
  73. Conway et al. (2017) (opens in a new tab)
  74. Conway et al. (2025) (opens in a new tab)
  75. Conway et al. (2026a) (opens in a new tab)
  76. Conway et al. (2026b) (opens in a new tab)
  77. Daly et al. (2019) (opens in a new tab)
  78. Dean et al. (2021) (opens in a new tab)
  79. DiBernardo et al. (2018) (opens in a new tab)
  80. Dodd et al. (2023) (opens in a new tab)
  81. Dougherty et al. (2025) (opens in a new tab)
  82. Dougherty et al. (2026) (opens in a new tab)
  83. Drug Discovery and Development (2026) (opens in a new tab)
  84. Dunner et al. (2006) (opens in a new tab)
  85. Duru and Fantino (2008) (opens in a new tab)
  86. eCQI Resource Center CMS159 (2026) (opens in a new tab)
  87. eCQI Resource Center CMS2 (2026) (opens in a new tab)
  88. Ellis et al. (2025a) (opens in a new tab)
  89. Ellis et al. (2025b) (opens in a new tab)
  90. EMA (2025) (opens in a new tab)
  91. Fabbri et al. (2021) (opens in a new tab)
  92. Fava (2003) (opens in a new tab)
  93. FDA (2018) (opens in a new tab)
  94. FDA psychedelic drugs guidance (2026) (opens in a new tab)
  95. FDA SAINT Neuromodulation System clearance (2022) (opens in a new tab)
  96. Fekadu et al. (2009a) (opens in a new tab)
  97. Fekadu et al. (2009b) (opens in a new tab)
  98. Fekadu et al. (2018) (opens in a new tab)
  99. Fife et al. (2018) (opens in a new tab)
  100. Flavin et al. (2026) (opens in a new tab)
  101. Gaynes et al. (2020) (opens in a new tab)
  102. George et al. (2010) (opens in a new tab)
  103. Goodwin et al. (2022) (opens in a new tab)
  104. Goodwin et al. (2023a) (opens in a new tab)
  105. Goodwin et al. (2023b) (opens in a new tab)
  106. Goodwin et al. (2024) (opens in a new tab)
  107. Goodwin et al. (2025a) (opens in a new tab)
  108. Goodwin et al. (2025b) (opens in a new tab)
  109. Goodwin et al. (2026) (opens in a new tab)
  110. Greenberg et al. (2023) (opens in a new tab)
  111. Gukasyan et al. (2023) (opens in a new tab)
  112. Guo et al. (2015) (opens in a new tab)
  113. Haikazian et al. (2023) (opens in a new tab)
  114. Halman et al. (2024) (opens in a new tab)
  115. Hamilton (1960) (opens in a new tab)
  116. Hasin et al. (2018) (opens in a new tab)
  117. Heerlein et al. (2021) (opens in a new tab)
  118. Heijnen et al. (2010) (opens in a new tab)
  119. Hengartner and Plöderl (2022) (opens in a new tab)
  120. Henssler et al. (2022) (opens in a new tab)
  121. Hieronymus et al. (2025) (opens in a new tab)
  122. Højlund et al. (2025) (opens in a new tab)
  123. Holze et al. (2023) (opens in a new tab)
  124. Hovmand et al. (2023) (opens in a new tab)
  125. Hsu et al. (2024) (opens in a new tab)
  126. Huneke et al. (2025) (opens in a new tab)
  127. ICER (2026) (opens in a new tab)
  128. ICER draft scope (2026) (opens in a new tab)
  129. ICER final evidence report (2019) (opens in a new tab)
  130. ICER TRD assessment page (2026) (opens in a new tab)
  131. Ijaz et al. (2018) (opens in a new tab)
  132. ISRCTN ISRCTN17905443 (opens in a new tab)
  133. ISRCTN ISRCTN17905443 basic results (2024) (opens in a new tab)
  134. Ivanova et al. (2010) (opens in a new tab)
  135. Iveson et al. (2026) (opens in a new tab)
  136. Jaffe et al. (2019) (opens in a new tab)
  137. Jamieson et al. (2023) (opens in a new tab)
  138. Jelovac et al. (2013) (opens in a new tab)
  139. Johnston et al. (2019) (opens in a new tab)
  140. Jungwirth et al. (2026) (opens in a new tab)
  141. Kaster et al. (2023) (opens in a new tab)
  142. Kern et al. (2023) (opens in a new tab)
  143. Keshavan (2026) (opens in a new tab)
  144. Kessler et al. (2018) (opens in a new tab)
  145. Kim and Na (2016) (opens in a new tab)
  146. Kirlić et al. (2025) (opens in a new tab)
  147. Kirlić et al. (2026) (opens in a new tab)
  148. Kratter et al. (2026) (opens in a new tab)
  149. Kubitz et al. (2013) (opens in a new tab)
  150. Lam et al. (2024) (opens in a new tab)
  151. Lenze et al. (2023) (opens in a new tab)
  152. Lerner et al. (2020) (opens in a new tab)
  153. Leucht et al. (2017) (opens in a new tab)
  154. Li et al. (2019) (opens in a new tab)
  155. Lithobid prescribing information (2022) (opens in a new tab)
  156. Lorentzen et al. (2020) (opens in a new tab)
  157. Lundberg et al. (2023) (opens in a new tab)
  158. Luoma et al. (2026) (opens in a new tab)
  159. Madras (2022) (opens in a new tab)
  160. Madsen et al. (2019) (opens in a new tab)
  161. Manevski et al. (2010) (opens in a new tab)
  162. Mann (2023) (opens in a new tab)
  163. Markopoulou et al. (2021) (opens in a new tab)
  164. Marseille et al. (2023) (opens in a new tab)
  165. Marwood et al. (2024) (opens in a new tab)
  166. McAllister-Williams et al. (2020) (opens in a new tab)
  167. McAllister-Williams et al. (2026) (opens in a new tab)
  168. McCrone et al. (2023) (opens in a new tab)
  169. McGrath et al. (2006) (opens in a new tab)
  170. McIntyre et al. (2023) (opens in a new tab)
  171. Menon et al. (2025) (opens in a new tab)
  172. Mertens et al. (2026) (opens in a new tab)
  173. Meshkat et al. (2025) (opens in a new tab)
  174. Mohamed et al. (2017) (opens in a new tab)
  175. Moncrieff et al. (2022) (opens in a new tab)
  176. Montgomery and Asberg (1979) (opens in a new tab)
  177. Mrazek et al. (2014) (opens in a new tab)
  178. Muthukumaraswamy et al. (2021) (opens in a new tab)
  179. Mutz et al. (2019) (opens in a new tab)
  180. Nayak et al. (2021) (opens in a new tab)
  181. Nayak et al. (2023) (opens in a new tab)
  182. NCQA Antidepressant Medication Management (opens in a new tab)
  183. NCQA Depression Remission or Response (opens in a new tab)
  184. NCQA Depression Screening and Follow-Up (opens in a new tab)
  185. NCQA HEDIS measure retirement plan (2023) (opens in a new tab)
  186. NCQA HEDIS MY 2025 changes (2024) (opens in a new tab)
  187. Nelson et al. (2014) (opens in a new tab)
  188. NICE (2015) (opens in a new tab)
  189. NICE (2020) (opens in a new tab)
  190. NICE (2022) (opens in a new tab)
  191. Nierenberg et al. (2006) (opens in a new tab)
  192. Nuñez et al. (2022) (opens in a new tab)
  193. Nygren et al. (2025) (opens in a new tab)
  194. O'Reardon et al. (2007) (opens in a new tab)
  195. Ochs-Ross et al. (2020) (opens in a new tab)
  196. Oregon Health Authority (opens in a new tab)
  197. Orsini et al. (2026) (opens in a new tab)
  198. Østergaard and Hieronymus (2023) (opens in a new tab)
  199. Papakostas et al. (2003) (opens in a new tab)
  200. Perez et al. (2023) (opens in a new tab)
  201. Pigott et al. (2023) (opens in a new tab)
  202. Pilon et al. (2019a) (opens in a new tab)
  203. Pilon et al. (2019b) (opens in a new tab)
  204. Pilon et al. (2021) (opens in a new tab)
  205. Popova et al. (2019) (opens in a new tab)
  206. Psych Congress Elevate COMP005 26-week abstract (2026) (opens in a new tab)
  207. Psych Congress Elevate phase 3 primary endpoint abstract (2026) (opens in a new tab)
  208. Qaseem et al. (2023) (opens in a new tab)
  209. Qaseem et al. (2026) (opens in a new tab)
  210. Rathod et al. (2022) (opens in a new tab)
  211. Reif et al. (2023) (opens in a new tab)
  212. Reutfors et al. (2018) (opens in a new tab)
  213. Reutfors et al. (2021) (opens in a new tab)
  214. Rexulti prescribing information (2026) (opens in a new tab)
  215. Rizvi et al. (2014) (opens in a new tab)
  216. Rosenblat et al. (2023) (opens in a new tab)
  217. Ross and Soeteman (2020) (opens in a new tab)
  218. Rucker et al. (2021) (opens in a new tab)
  219. Rucker et al. (2022) (opens in a new tab)
  220. Rucker et al. (2026) (opens in a new tab)
  221. Ruhé et al. (2012) (opens in a new tab)
  222. Runia et al. (2022) (opens in a new tab)
  223. Rush et al. (2006a) (opens in a new tab)
  224. Rush et al. (2006b) (opens in a new tab)
  225. Rush et al. (2025) (opens in a new tab)
  226. Sackeim (2001) (opens in a new tab)
  227. SAMHSA (2026) (opens in a new tab)
  228. Sarparast et al. (2022) (opens in a new tab)
  229. Semkovska and McLoughlin (2010) (opens in a new tab)
  230. Seroquel XR prescribing information (2025) (opens in a new tab)
  231. Sforzini et al. (2022) (opens in a new tab)
  232. Silva-Carvalho et al. (2026) (opens in a new tab)
  233. Smith et al. (2026) (opens in a new tab)
  234. Spielmans et al. (2013) (opens in a new tab)
  235. Spravato prescribing information (2025) (opens in a new tab)
  236. Strawbridge et al. (2023) (opens in a new tab)
  237. Syed et al. (2026) (opens in a new tab)
  238. Symbyax prescribing information (2025) (opens in a new tab)
  239. Szukis et al. (2021) (opens in a new tab)
  240. Tai et al. (2021) (opens in a new tab)
  241. Thase and Rush (1997) (opens in a new tab)
  242. Thomann et al. (2024) (opens in a new tab)
  243. Thomas et al. (2013) (opens in a new tab)
  244. Trivedi et al. (2006) (opens in a new tab)
  245. Tsai et al. (2026) (opens in a new tab)
  246. Turkoz et al. (2021) (opens in a new tab)
  247. UK ECT Review Group (2003) (opens in a new tab)
  248. VA/DoD (2022) (opens in a new tab)
  249. van Bronswijk et al. (2019) (opens in a new tab)
  250. Vraylar prescribing information (2025) (opens in a new tab)
  251. White House (2026) (opens in a new tab)
  252. Wiles et al. (2013) (opens in a new tab)
  253. Wiles et al. (2016) (opens in a new tab)
  254. Williams et al. (2026) (opens in a new tab)
  255. Wolff et al. (2026) (opens in a new tab)
  256. Young et al. (2025) (opens in a new tab)
  257. Zaki et al. (2023) (opens in a new tab)
  258. Zhdanava et al. (2020) (opens in a new tab)
  259. Zhdanava et al. (2021) (opens in a new tab)
  260. Ziadi and Park (2026) (opens in a new tab)
  261. Zimmerman et al. (2004) (opens in a new tab)